SECTION

#Cost Control

Total 4 related articles

Live wire →

NewsTag

Featured

Dauch Raises Full-Year Guidance: Revenue Target $10.6-$10.8B, EBITDA Range Narrowed

Lead report

美股

Lead report

Dauch Raises Full-Year Guidance: Revenue Target $10.6-$10.8B, EBITDA Range Narrowed

Dauch lifts full-year sales outlook to $10.6-$10.8 billion, narrows EBITDA guidance to $1.36-$1.425 billion, and achieves $70 million in annualized integration savings, signaling strong cost control and emerging business growth.

YayaNews2026-08-08 05:533 min

来源: Seeking Alpha

美股

SunPower Q3 Revenue Outlook Exceeds $75 Million, Narrows Non-GAAP Operating Loss to Under $1 Million

SunPower projects Q3 revenue above $75 million and a non-GAAP operating loss under $1 million, signaling effective cost controls. Shares rose in after-hours trading.

YayaNews2026-07-29 08:483 min来源: Seeking Alpha

SunPower Q3 Revenue Outlook Exceeds $75 Million, Narrows Non-GAAP Operating Loss to Under $1 Million

美股

Domino's Pizza Q2 2026 Earnings Preview: Same-Store Sales, Cost Control, and Growth Outlook

A deep dive into Domino's Pizza's Q2 2026 earnings, covering U.S. same-store sales trends, international expansion, ingredient and labor cost pressures, digital delivery advantages, and valuation sentiment.

YayaNews2026-07-18 02:123 min来源: Seeking Alpha

Domino's Pizza Q2 2026 Earnings Preview: Same-Store Sales, Cost Control, and Growth Outlook

More Related Articles

美股

Sonoma Pharmaceuticals Earnings: Revenue of $5.56 Million but EPS Loss of $0.33, Market Eyes Profitability Outlook

Sonoma Pharmaceuticals reported a GAAP loss of $0.33 per share on revenue of $5.56 million. The analysis covers cost control, industry competition, and future turnaround strategies, with investors focused on cash flow and pipeline progress.

YayaNews2026-06-17 04:263 min来源: Seeking Alpha

Sonoma Pharmaceuticals Earnings: Revenue of $5.56 Million but EPS Loss of $0.33, Market Eyes Profitability Outlook